Initiating hormone replacement therapy (HRT) within a five-year window following menopause onset appears to reduce the likelihood of developing Alzheimer’s disease. However, commencing HRT at a later stage in life may yield the opposite outcome, indicating that the precise timing of HRT significantly influences its impact on the brain.
Compared to men, women face a heightened risk of developing Alzheimer’s disease, a disparity that becomes particularly pronounced after menopause. This increased susceptibility may be linked to the decline in estrogen levels. Estrogen plays a crucial role in regulating energy production and inflammation within the brain. Consequently, HRT has been considered a potential strategy for mitigating Alzheimer’s risk in post-menopausal women. Despite this potential, research into its efficacy has yielded varied results.
The hormonal fluctuations experienced during the perimenopausal period can lead to cognitive challenges. Simultaneously, researchers are discovering that this phase represents a critical opportunity for safeguarding long-term brain health.
Fnu Vaibhav, affiliated with Pandit Bhagwat Dayal Sharma University of Health Sciences in India, along with his colleagues, conducted an extensive analysis of Alzheimer’s disease incidence. Their research encompassed 53 distinct studies, involving a cumulative total of over 8.4 million post-menopausal participants. The objective was to synthesize existing data and identify patterns related to HRT use and Alzheimer’s risk.
Their findings revealed a notable divergence based on study type. In randomized controlled trials, participants undergoing HRT demonstrated, on average, a 38 percent increased risk of developing Alzheimer’s when contrasted with those not receiving HRT. This contrasts sharply with observational studies, which indicated a 22 percent reduced risk of Alzheimer’s disease among individuals using HRT. Vaibhav presented these findings on September 15th at a meeting of the American Neurological Association in Maryland.
Vaibhav suggests that this significant disparity can be primarily attributed to age. He explains that the majority of participants in the randomized controlled trials were aged 65 or older. In contrast, individuals involved in observational studies tended to be younger. Further detailed analysis indicated that participants who initiated HRT within five years of menopause experienced, on average, a 32 percent lower risk of Alzheimer’s disease. This observation remained consistent across follow-up periods that varied from a minimum of five years in some studies to extended durations up to the participant’s lifetime until death in others.
“This menopausal transition is actually a neurological transition,” remarked Roberta Brinton from the University of Arizona, who was not involved in the research. As estrogen levels diminish, the brain is compelled to find alternative mechanisms for generating energy. Emerging evidence suggests that the brain might resort to a form of self-cannibalization, utilizing essential compounds vital for its maintenance and function as an energy source. This process could potentially accelerate neurodegeneration. Brinton posits that commencing HRT during or shortly after menopause might interrupt this shift. However, if the brain has already undergone this fundamental alteration, it is possible that HRT may no longer be effective.
“We need more studies to find out the solution to this confusion,” stated Vaibhav. He emphasized that without a more precise understanding of HRT’s multifaceted effects, “women might be missing out on the benefits, or women might be at harm.”